Greenwich LifeSciences, Inc.
Financial highlights
| Metric | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 | FY December 31, 2020 |
|---|---|---|---|---|---|
| Operating income | -$16.0M | -$9.3M | -$8.0M | -$4.6M | -$1.9M |
| Operating expenses | $16.0M | $9.3M | $8.0M | $4.6M | $1.9M |
| Cash from operations | -$7.3M | -$6.5M | -$6.2M | -$4.3M | -$1.2M |
| Share repurchases | — | $7.5M | $7.5M | — | — |
| Total assets | $4.1M | $7.0M | $13.5M | $27.2M | $28.7M |
| Total liabilities | $1.6M | $294,406 | $262,905 | $385,172 | $1.0M |
Shares outstanding 14.7M
Annual filing data through FY ended December 31, 2024; float as of July 2, 2026.